In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar

Devendra Bansal, Rakesh Sehgal, Yogesh Chawla, Ramesh Chander Mahajan, Nancy Malla

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Background: Amoebiases is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. Methods: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC50) of clinical isolates and standard reference strain of E. histolytica (HMI: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. Results: The results showed that all clinical isolates had a higher IC50 compared to reference strain to all four drugs. E. histolytica isolates appeared to be more susceptible [IC50 (μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC50(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC50 (μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. Conclusions: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs.

Original languageEnglish
Article number27
JournalAnnals of Clinical Microbiology and Antimicrobials
Volume3
DOIs
Publication statusPublished - 21 Dec 2004
Externally publishedYes

Fingerprint

Entamoeba
Entamoeba histolytica
Inhibitory Concentration 50
Emetine
Tinidazole
Pharmaceutical Preparations
Metronidazole
Chloroquine
In Vitro Techniques
India
Public Health

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar. / Bansal, Devendra; Sehgal, Rakesh; Chawla, Yogesh; Mahajan, Ramesh Chander; Malla, Nancy.

In: Annals of Clinical Microbiology and Antimicrobials, Vol. 3, 27, 21.12.2004.

Research output: Contribution to journalArticle

@article{c516435de75349fc83d94de195e23926,
title = "In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar",
abstract = "Background: Amoebiases is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. Methods: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC50) of clinical isolates and standard reference strain of E. histolytica (HMI: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. Results: The results showed that all clinical isolates had a higher IC50 compared to reference strain to all four drugs. E. histolytica isolates appeared to be more susceptible [IC50 (μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC50(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC50 (μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. Conclusions: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs.",
author = "Devendra Bansal and Rakesh Sehgal and Yogesh Chawla and Mahajan, {Ramesh Chander} and Nancy Malla",
year = "2004",
month = "12",
day = "21",
doi = "10.1186/1476-0711-3-27",
language = "English",
volume = "3",
journal = "Annals of Clinical Microbiology and Antimicrobials",
issn = "1476-0711",
publisher = "BioMed Central",

}

TY - JOUR

T1 - In vitro activity of antiamoebic drugs against clinical isolates of Entamoeba histolytica and Entamoeba dispar

AU - Bansal, Devendra

AU - Sehgal, Rakesh

AU - Chawla, Yogesh

AU - Mahajan, Ramesh Chander

AU - Malla, Nancy

PY - 2004/12/21

Y1 - 2004/12/21

N2 - Background: Amoebiases is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. Methods: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC50) of clinical isolates and standard reference strain of E. histolytica (HMI: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. Results: The results showed that all clinical isolates had a higher IC50 compared to reference strain to all four drugs. E. histolytica isolates appeared to be more susceptible [IC50 (μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC50(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC50 (μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. Conclusions: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs.

AB - Background: Amoebiases is a major public health problem in tropical and subtropical countries. Although a number of antiamoebic agents are used for its treatment, yet the susceptibility data on clinical isolates of Entamoeba histolytica and Entamoeba dispar are not available. Therefore, the present study was aimed to assess the in vitro susceptibility of clinical isolates of E. histolytica and E. dispar to metronidazole, chloroquine, emetine and tinidazole. Methods: A total of 45 clinical isolates (15 E. histolytica and 30 E. dispar) were maintained in polyxenic cultures followed by monoxenic cultures. In vitro drug sensitivity (IC50) of clinical isolates and standard reference strain of E. histolytica (HMI: IMSS) was assessed by nitro blue tetrazolium (NBT) reduction assay after exposure to various concentrations of each drug. Results: The results showed that all clinical isolates had a higher IC50 compared to reference strain to all four drugs. E. histolytica isolates appeared to be more susceptible [IC50 (μm) 13.2,26.3,31.2 and 12.4] compared to E. dispar isolates [IC50(μm) 15.6,28.9,32.8 and 13.2] and the reference strain of E. histolytica [IC50 (μm) 9.5, 15.5, 29.9 and 10.2] to the metronidazole, chloroquine, emetine and tinidazole respectively. Conclusions: The results indicate that till date, Entamoeba isolates in India do not seem to be resistant to the commonly used antiamoebic drugs.

UR - http://www.scopus.com/inward/record.url?scp=33750492287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750492287&partnerID=8YFLogxK

U2 - 10.1186/1476-0711-3-27

DO - 10.1186/1476-0711-3-27

M3 - Article

VL - 3

JO - Annals of Clinical Microbiology and Antimicrobials

JF - Annals of Clinical Microbiology and Antimicrobials

SN - 1476-0711

M1 - 27

ER -